Profund Advisors LLC Boosts Stock Position in Gilead Sciences, Inc. $GILD

Profund Advisors LLC raised its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 13.2% during the 4th quarter, Holdings Channel.com reports. The firm owned 135,953 shares of the biopharmaceutical company’s stock after buying an additional 15,824 shares during the quarter. Profund Advisors LLC’s holdings in Gilead Sciences were worth $16,687,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in GILD. Ares Financial Consulting LLC purchased a new position in Gilead Sciences in the fourth quarter valued at about $28,000. Financial Consulate Inc. grew its stake in Gilead Sciences by 85.8% in the fourth quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 109 shares during the last quarter. North Star Investment Management Corp. grew its stake in Gilead Sciences by 54.8% in the fourth quarter. North Star Investment Management Corp. now owns 243 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 86 shares during the last quarter. MTM Investment Management LLC grew its stake in Gilead Sciences by 176.0% in the third quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 176 shares during the last quarter. Finally, BOCHK Asset Management Ltd purchased a new position in Gilead Sciences in the fourth quarter valued at about $31,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling

In related news, insider Johanna Mercier sold 28,000 shares of the stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $131.29, for a total value of $3,676,120.00. Following the transaction, the insider owned 125,779 shares in the company, valued at approximately $16,513,524.91. This represents a 18.21% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $132.27, for a total transaction of $396,810.00. Following the completion of the transaction, the chief financial officer owned 173,191 shares in the company, valued at approximately $22,907,973.57. This trade represents a 1.70% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 63,000 shares of company stock worth $8,523,570. 0.30% of the stock is owned by company insiders.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $129.67 on Tuesday. The business’s 50 day moving average price is $137.46 and its 200 day moving average price is $133.40. The firm has a market cap of $160.99 billion, a P/E ratio of 17.67 and a beta of 0.31. Gilead Sciences, Inc. has a 52 week low of $102.84 and a 52 week high of $157.29. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, topping the consensus estimate of $1.91 by $0.12. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The company had revenue of $6.96 billion for the quarter, compared to the consensus estimate of $6.91 billion. During the same quarter in the prior year, the company earned $1.81 EPS. Gilead Sciences’s quarterly revenue was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. On average, sell-side analysts expect that Gilead Sciences, Inc. will post -0.78 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, June 29th. Investors of record on Monday, June 15th will be issued a $0.82 dividend. This represents a $3.28 annualized dividend and a yield of 2.5%. The ex-dividend date is Monday, June 15th. Gilead Sciences’s dividend payout ratio is 44.69%.

Analysts Set New Price Targets

Several equities analysts have issued reports on the company. Morgan Stanley cut their target price on Gilead Sciences from $175.00 to $168.00 in a research note on Friday, May 8th. Barclays began coverage on Gilead Sciences in a research note on Friday, February 20th. They set an “equal weight” rating and a $155.00 price target on the stock. The Goldman Sachs Group boosted their price target on Gilead Sciences from $125.00 to $130.00 and gave the stock a “neutral” rating in a research note on Friday, April 17th. Wolfe Research boosted their price target on Gilead Sciences from $155.00 to $170.00 and gave the stock an “outperform” rating in a research note on Thursday, February 12th. Finally, Cantor Fitzgerald dropped their price target on Gilead Sciences from $155.00 to $115.00 and set an “overweight” rating on the stock in a research note on Friday, April 10th. Twenty-four analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, Gilead Sciences has a consensus rating of “Moderate Buy” and a consensus price target of $157.04.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.